Sushupta M Vijapur1, Leah E Vaughan1, Nabil Awan1, Dominic DiSanto1, Gina P McKernan2, Amy K Wagner3. 1. Department of Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, PA, USA. 2. Department of Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, PA, USA; Human Engineering Research Laboratories, University of Pittsburgh, Pittsburgh, PA, USA. 3. Department of Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, PA, USA; Safar Center for Resuscitation Research, University of Pittsburgh, Pittsburgh, PA, USA; Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA, USA; Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA, USA; Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: wagnerak@upmc.edu.
Abstract
BACKGROUND: Inflammatory cascades following traumatic brain injury (TBI) can have both beneficial and detrimental effects on recovery. Single biomarker studies do not adequately reflect the major arms of immunity and their relationships to long-term outcomes. Thus, we applied treelet transform (TT) analysis to identify clusters of interrelated inflammatory markers reflecting major components of systemic immune function for which substantial variation exists among individuals with moderate-to-severe TBI. METHODS: Serial blood samples from 221 adults with moderate-to-severe TBI were collected over 1-6 months post-injury (n = 607 samples). Samples were assayed for 33 inflammatory markers using Millipore multiplex technology. TT was applied to standardized mean biomarker values generated to identify latent patterns of correlated markers. Treelet clusters (TC) were characterized by biomarkers related to adaptive immunity (TC1), innate immunity (TC2), soluble molecules (TC3), allergy immunity (TC4), and chemokines (TC5). For each TC, a score was generated as the linear combination of standardized biomarker concentrations and cluster load for each individual in the cohort. Ordinal logistic or linear regression was used to test associations between TC scores and 6- and 12-month Glasgow Outcome Scale (GOS), Disability Rating Scale (DRS), and covariates. RESULTS: When adjusting for clinical covariates, TC5 was significantly associated with 6-month GOS (odds ratio, OR = 1.44; p-value, p = 0.025) and 6-month DRS scores (OR = 1.46; p = 0.013). TC5 relationships were attenuated when including all TC scores in the model (GOS: OR = 1.29, p = 0.163; DRS: OR = 1.33, p = 0.100). When adjusting for all TC scores and covariates, only TC3 was associated with 6- and 12-month GOS (OR = 1.32, p = 0.041; OR = 1.39, p = 0.002) and also 6- and 12-month DRS (OR = 1.38, p = 0.016; OR = 1.58, p = 0.0002). When applying TT to inflammation markers significantly associated with 6-month GOS, multivariate modeling confirmed that TC3 remained significantly associated with GOS. Biomarker cluster membership remained consistent between the GOS-specific dendrogram and overall dendrogram. CONCLUSIONS: TT effectively characterized chronic, systemic immunity among a cohort of individuals with moderate-to-severe TBI. We posit that chronic chemokine levels are effector molecules propagating cellular immune dysfunction, while chronic soluble receptors are inflammatory damage readouts perpetuated, in part, by persistent dysfunctional cellular immunity to impact neuro-recovery.
BACKGROUND: Inflammatory cascades following traumatic brain injury (TBI) can have both beneficial and detrimental effects on recovery. Single biomarker studies do not adequately reflect the major arms of immunity and their relationships to long-term outcomes. Thus, we applied treelet transform (TT) analysis to identify clusters of interrelated inflammatory markers reflecting major components of systemic immune function for which substantial variation exists among individuals with moderate-to-severe TBI. METHODS: Serial blood samples from 221 adults with moderate-to-severe TBI were collected over 1-6 months post-injury (n = 607 samples). Samples were assayed for 33 inflammatory markers using Millipore multiplex technology. TT was applied to standardized mean biomarker values generated to identify latent patterns of correlated markers. Treelet clusters (TC) were characterized by biomarkers related to adaptive immunity (TC1), innate immunity (TC2), soluble molecules (TC3), allergy immunity (TC4), and chemokines (TC5). For each TC, a score was generated as the linear combination of standardized biomarker concentrations and cluster load for each individual in the cohort. Ordinal logistic or linear regression was used to test associations between TC scores and 6- and 12-month Glasgow Outcome Scale (GOS), Disability Rating Scale (DRS), and covariates. RESULTS: When adjusting for clinical covariates, TC5 was significantly associated with 6-month GOS (odds ratio, OR = 1.44; p-value, p = 0.025) and 6-month DRS scores (OR = 1.46; p = 0.013). TC5 relationships were attenuated when including all TC scores in the model (GOS: OR = 1.29, p = 0.163; DRS: OR = 1.33, p = 0.100). When adjusting for all TC scores and covariates, only TC3 was associated with 6- and 12-month GOS (OR = 1.32, p = 0.041; OR = 1.39, p = 0.002) and also 6- and 12-month DRS (OR = 1.38, p = 0.016; OR = 1.58, p = 0.0002). When applying TT to inflammation markers significantly associated with 6-month GOS, multivariate modeling confirmed that TC3 remained significantly associated with GOS. Biomarker cluster membership remained consistent between the GOS-specific dendrogram and overall dendrogram. CONCLUSIONS: TT effectively characterized chronic, systemic immunity among a cohort of individuals with moderate-to-severe TBI. We posit that chronic chemokine levels are effector molecules propagating cellular immune dysfunction, while chronic soluble receptors are inflammatory damage readouts perpetuated, in part, by persistent dysfunctional cellular immunity to impact neuro-recovery.
Authors: David W Wright; Sharon D Yeatts; Robert Silbergleit; Yuko Y Palesch; Vicki S Hertzberg; Michael Frankel; Felicia C Goldstein; Angela F Caveney; Harriet Howlett-Smith; Erin M Bengelink; Geoffrey T Manley; Lisa H Merck; L Scott Janis; William G Barsan Journal: N Engl J Med Date: 2014-12-10 Impact factor: 91.245
Authors: Claudia S Robertson; H Julia Hannay; José-Miguel Yamal; Shankar Gopinath; J Clay Goodman; Barbara C Tilley; Athena Baldwin; Lucia Rivera Lara; Hector Saucedo-Crespo; Osama Ahmed; Santhosh Sadasivan; Luciano Ponce; Jovanny Cruz-Navarro; Hazem Shahin; Imoigele P Aisiku; Pratik Doshi; Alex Valadka; Leslie Neipert; Jace M Waguspack; M Laura Rubin; Julia S Benoit; Paul Swank Journal: JAMA Date: 2014-07-02 Impact factor: 56.272
Authors: T Riegger; S Conrad; H J Schluesener; H-P Kaps; A Badke; C Baron; J Gerstein; K Dietz; M Abdizahdeh; J M Schwab Journal: Neuroscience Date: 2008-08-22 Impact factor: 3.590
Authors: C Kirchhoff; S Buhmann; V Bogner; J Stegmaier; B A Leidel; V Braunstein; W Mutschler; P Biberthaler Journal: Eur J Med Res Date: 2008-10-27 Impact factor: 2.175
Authors: Miranda J Munoz; Raj G Kumar; Byung-Mo Oh; Yvette P Conley; Zhensheng Wang; Michelle D Failla; Amy K Wagner Journal: Front Mol Neurosci Date: 2017-03-09 Impact factor: 5.639
Authors: Jennifer Rusiecki; Lynn I Levin; Li Wang; Celia Byrne; Jayasree Krishnamurthy; Ligong Chen; Zygmunt Galdzicki; Louis M French Journal: J Neuroinflammation Date: 2020-01-13 Impact factor: 8.322